Genetic variations in the ADCK1 gene predict paliperidone palmitate efficacy in Han Chinese patients with schizophrenia.
Yun-Ai Su, Chad Bousman, Qian Li, Ji-Tao Li, Jing-Yu Lin, Tian-Mei Si
J Neural Transm (Vienna) | Published : 2019
Genome-wide association study results have linked ADCK1 genetic variation with paliperidone efficacy in a European cohort. However, the generalizability of this locus to non-European populations is unknown. Han Chinese schizophrenia patients (n = 159) were treated with paliperidone palmitate and symptom severity was assessed over 3 months. Examination of 13 ADCK1 genetic variants revealed two single nucleotide polymorphisms (rs12590199, rs11159291) and one haplotype (rs2364747-rs12590199) associated with paliperidone palmitate response. Future work into ADCK1's function and its potential interaction with paliperidone is warranted.
Awarded by National Natural Science Foundation of China
Awarded by Capital Medical Development Research Fund
Awarded by Beijing Municipal Science and Technology Project